Reactogenecity of indigenously produced measles vaccine.
Indian Pediatr
;
1996 Oct; 33(10): 827-31
Artículo
en Inglés
| IMSEAR
| ID: sea-9758
ABSTRACT
OBJECTIVE:
To assess the safety and reactogenecity of indigenously produced measles vaccine derived from EZ strain.DESIGN:
A longitudinal clinical follow up after vaccination.SETTING:
Hospital based and home follow up, as required.SUBJECTS:
12,470 children, 9 to 15 months old, immunized with measles vaccine of EZ strain, in accordance with the National Immunization Schedule, at five centers.METHODS:
A clinical follow up of children at 1 day, 1 week, 2 weeks, 3 weeks and 6 weeks after measles vaccination. A detailed clinical neurological examination in children showing side effects.RESULTS:
Mild side effects were documented in 31%. Of these, 90% were seen in the first two weeks, out of which two thirds were seen during the first week. Commonest side effects were coryza (10%), fever (9.8%), cough (3.2%) and diarrhea (3.2%). Convulsions, with no later sequelae were documented in 2 cases only.CONCLUSIONS:
Measles vaccine manufactured in India, using EZ strain is a safe vaccine. It has a level of reactogenecity including neurological aspects, lower than that reported in India with the Schwarz strain vaccine.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Humanos
/
Vacuna Antisarampión
/
Estudios Longitudinales
/
India
/
Lactante
Tipo de estudio:
Estudio observacional
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Indian Pediatr
Año:
1996
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS